Mostrando 3 resultados de: 3
Filtros aplicados
Área temáticas
Enfermedades(3)
Farmacología y terapéutica(2)
Ginecología, obstetricia, pediatría, geriatría(2)
Origen
scopus(3)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusNimotuzumab for Patients With Inoperable Cancer of the Head and Neck
ReviewAbstract: EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasisPalabras claves:eGFR, head and neck, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Iznaga-Escobar N., Mazorra Z., Mestre Fernández B., Tania CrombetFuentes:scopusThymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
ArticleAbstract: Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy rPalabras claves:Biomodulina T, CIMAvax-EGF, naïve T cells, Non-small-cell lung cancer, PD-1, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Díaz M., González A., Hernández J.d.l.C., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Molina M.d.l.A., Peña Y., Pereira K., Portela S., Ramos R., Reyes M.C., Saavedra Hernández D., Suárez G.M., Tania CrombetFuentes:scopus